Cesar Perez, Director of Drug Development at Lake Nona DDU of Florida Cancer Specialists and Research Institute, shared on LinkedIn:
“Proud to share our recent publication in JCO Oncology Advances:
“Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF-Altered Solid Tumors or NRAS-Mutant Melanoma.”
This international Phase I study demonstrates that exarafenib achieved an acceptable safety profile with encouraging antitumor activity, particularly in BRAF class II alterations and NRAS-mutant tumors – an area of major unmet need.
Key highlights:
• RP2D established at 300 mg BID
• Manageable and mostly low-grade toxicity
• Clinical activity across multiple tumor types
• Notable signals in fusion-driven and class II BRAF disease
A special shout-out to my partner and SCRI Melanoma Lead Dr. Meredith McKean for her leadership and major contributions to this work – and to our outstanding global investigator team.
Huge thanks to the patients and families who make early-phase research possible.
Excited to see how this program evolves, including rational combinations moving forward.”
Title: Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF-Altered Solid Tumors or NRAS-Mutant Melanoma
Authors: Valentina Gambardella, Meredith McKean, Richard Kim, Shumei Kato, Philippe Cassier, Janice M. Mehnert, Bartosz Chmielowski, Caroline Gaudy-Marqueste, Christopher T. Chen, David Planchard, Caicun Zhou, Chia-Chi Lin, Tadashi Manabe, Trever Bivona, Caro Unger, Adrianne Kelly, Xiaowei Guan, Paul Severson, Gerri Lee, Richard Thomas Williams, Alexander I. Spira, Georgina V. Long, Cesar A. Perez, Maria Gonzalez-Cao
More posts featuring Cesar Perez on OncoDaily.